Japan launches world's first viral drug for esophageal cancer
Japan begins commercial sales of the first viral therapy for esophageal cancer, developed by Oncolys BioPharma, using genetically modified viruses.
Japan has commenced commercial sales of the world's first viral therapy for esophageal cancer, developed by Oncolys BioPharma. This groundbreaking drug utilizes genetically modified viruses that specifically target and eliminate cancer cells while leaving healthy tissue unharmed. According to the Nikkei news agency, the Japanese announcement highlights the significance of this innovative treatment method.
Oncolys BioPharma, headquartered in Tokyo, overcame substantial regulatory challenges in Japan, where the production of such viruses necessitates stringent quality control measures. The drug's development process involved a unique testing protocol, as its therapeutic effects might not manifest for several weeks, contingent upon the extent of the virus's spread within the tumor.
Oncolytic viruses exhibit the remarkable ability to proliferate inside cancer cells, resulting in their destruction from within and concurrently triggering the body's immune response.
Written by urgent.news from Ajel English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
